Table 3. Summary of solicited reactogenicity.
| Symptoms Intensity | DNA Prime (n = 44) | IIV3 Prime (n = 31) | IIV3 Boosta (n = 75) |
|---|---|---|---|
| Local reactogenicity, participants (%) | |||
| PAIN/TENDERNESS | |||
| None | 3 (6.8%) | 13 (41.9%) | 30 (40.0%) |
| Mild | 41 (93.2%) | 16 (51.6%) | 42 (56.0%) |
| Moderate | 0 (0.0%) | 2 (6.5%) | 3 (4.0%) |
| SWELLING | |||
| None | 29 (65.9%) | 31 (100.0%) | 73 (97.3%) |
| Mild | 11 (25.0%) | 0 (0.0%) | 1 (1.3%) |
| Moderate | 4 (9.1%) | 0 (0.0%) | 1 (1.3%) |
| REDNESS | |||
| None | 21 (47.7%) | 26 (83.9%) | 65 (86.7%) |
| Mild | 22 (50.0%) | 4 (12.9%) | 7 (9.3%) |
| Moderate | 1 (2.3%) | 1 (3.2%) | 3 (4.0%) |
| ANY LOCAL SYMPTOM | |||
| None | 3 (6.8%) | 12 (38.7%) | 29 (38.7%) |
| Mild | 37 (84.1%) | 16 (51.6%) | 40 (53.3%) |
| Moderate | 4 (9.1%) | 3 (9.7%) | 6 (8.0%) |
| Systemic reactogenicity, participants (%) | |||
| MALAISE | |||
| None | 36 (81.8%) | 25 (80.6%) | 57 (76.0%) |
| Mild | 8 (18.2%) | 6 (19.4%) | 13 (17.3%) |
| Moderate | 0 (0.0%) | 0 (0.0%) | 5 (6.7%) |
| MYALGIA | |||
| None | 37 (84.1%) | 28 (90.3%) | 68 (90.7%) |
| Mild | 7 (15.9%) | 3 (9.7%) | 6 (8.0%) |
| Moderate | 0 (0.0%) | 0 (0.0%) | 1 (1.3%) |
| HEADACHE | |||
| None | 31 (70.5%) | 25 (80.6%) | 59 (78.7%) |
| Mild | 11 (25.0%) | 5 (16.1%) | 13 (17.3%) |
| Moderate | 2 (4.5%) | 1 (3.2%) | 3 (4.0%) |
| CHILLS | |||
| None | 42 (95.5%) | 29 (93.5%) | 70 (93.3%) |
| Mild | 2 (4.5%) | 1 (3.2%) | 5 (6.7%) |
| Moderate | 0 (0.0%) | 1 (3.2%) | 0 (0.0%) |
| NAUSEA | |||
| None | 40 (90.9%) | 31 (100.0%) | 67 (89.3%) |
| Mild | 4 (9.1%) | 0 (0.0%) | 6 (8.0%) |
| Moderate | 0 (0.0%) | 0 (0.0%) | 2 (2.7%) |
| TEMPERATURE | |||
| None | 43 (97.7%) | 31 (100.0%) | 73 (97.3%) |
| Mild | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| Moderate | 1 (2.3%) | 0 (0.0%) | 1 (1.3%) |
| Severe | 0 (0.0%) | 0 (0.0%) | 1 (1.3%) |
| ANY SYSTEMIC SYMPTOM | |||
| None | 27 (61.4%) | 21 (67.7%) | 49 (65.3%) |
| Mild | 15 (34.1%) | 9 (29.0%) | 19 (25.3%) |
| Moderate | 2 (4.5%) | 1 (3.2%) | 6 (8.0%) |
| Severe | 0 (0.0%) | 0 (0.0%) | 1 (1.3%) |
Solicited reactogenicity was collected for 7 days after each vaccination. Each vaccine recipient was counted once at worst severity for any local and systemic parameter.
aIIV3 boost symptoms were consolidated for all vaccine regimens, as no differences were observed between groups.